StocksMediumUpdated•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
Denali Therapeutics Shares Jump 9.8% on Q3 Adjusted Earnings Beat
Key Facts
1Denali reported Q3 net income of $70.1 million, bolstered by a one-time $194 million gain from the sale of a Priority Review Voucher.
2AVLAYAH net product revenue accelerated to $17.8 million, with Q4 guidance projected between $30.0 million and $32.0 million.
3The company ended the quarter with $1.0 billion in cash, cash equivalents, and marketable securities.
Denali Therapeutics reported adjusted earnings per share of $0.37 for the third quarter of 2026, significantly beating analyst estimates of a $0.37 loss per share. GlobeNewswire reported that the company achieved net income of $70.1 million, driven by a $194 million gain from the sale of a Priority Review Voucher.
Shares of Denali Therapeutics rose 9.8% in after-hours trading following the announcement, after DNLI had closed at $18.86 on November 2, 2026. Net product revenue for AVLAYAH reached $17.8 million during the quarter, and the company expects revenue for the product to grow to between $30.0 million and $32.0 million in the fourth quarter of 2026.